CL2020003339A1 - Inhibidores de ectonucleotidasa y métodos de uso de los mismos - Google Patents

Inhibidores de ectonucleotidasa y métodos de uso de los mismos

Info

Publication number
CL2020003339A1
CL2020003339A1 CL2020003339A CL2020003339A CL2020003339A1 CL 2020003339 A1 CL2020003339 A1 CL 2020003339A1 CL 2020003339 A CL2020003339 A CL 2020003339A CL 2020003339 A CL2020003339 A CL 2020003339A CL 2020003339 A1 CL2020003339 A1 CL 2020003339A1
Authority
CL
Chile
Prior art keywords
methods
ectonucleotidase inhibitors
ectonucleotidase
inhibitors
heterocyclic compounds
Prior art date
Application number
CL2020003339A
Other languages
English (en)
Inventor
Lijing Chen
Roland Joseph Billedeau
Jim Li
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CL2020003339A1 publication Critical patent/CL2020003339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a nuevos compuestos heterocíclicos y preparaciones farmacéuticas de los mismos. La invención se refiere además a métodos para tratar o prevenir el cáncer usando los nuevos compuestos heterocíclicos de la invención.
CL2020003339A 2018-06-21 2020-12-21 Inhibidores de ectonucleotidasa y métodos de uso de los mismos CL2020003339A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688225P 2018-06-21 2018-06-21
US201962827505P 2019-04-01 2019-04-01

Publications (1)

Publication Number Publication Date
CL2020003339A1 true CL2020003339A1 (es) 2021-06-25

Family

ID=68981317

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003339A CL2020003339A1 (es) 2018-06-21 2020-12-21 Inhibidores de ectonucleotidasa y métodos de uso de los mismos

Country Status (16)

Country Link
US (2) US11078228B2 (es)
EP (1) EP3810617A4 (es)
JP (1) JP2021529172A (es)
KR (1) KR20210024561A (es)
CN (1) CN112888696B (es)
AU (1) AU2019288495B2 (es)
BR (1) BR112020025132B1 (es)
CA (1) CA3104088A1 (es)
CL (1) CL2020003339A1 (es)
CO (1) CO2021000049A2 (es)
IL (1) IL279475A (es)
MX (1) MX2020013320A (es)
PH (1) PH12020552214A1 (es)
SG (1) SG11202012001YA (es)
TW (1) TW202010750A (es)
WO (1) WO2019246403A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012327A2 (pt) * 2016-12-22 2019-11-19 Calithera Biosciences Inc inibidores de ectonucleotidase e métodos de uso dos mesmos
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
AU2019288495B2 (en) 2018-06-21 2024-02-08 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
CN114008048A (zh) * 2019-06-20 2022-02-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
BR112022008365A2 (pt) 2019-10-30 2023-03-28 Oric Pharmaceuticals Inc Inibidores de cd73
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN115873049B (zh) * 2023-02-13 2023-05-02 北京先通国际医药科技股份有限公司 腺苷的制备方法及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008669B1 (ko) 1991-04-24 1996-06-28 야마사 쇼오유 가부시끼가이샤 1-β-D-아라비노푸라노실-(E)-5-(2-할로게노비닐) 우라실 유도체
AU5449094A (en) 1992-11-02 1994-05-24 Affymax Technologies N.V. Novel photoreactive protecting groups
US5635608A (en) 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
NL1005244C2 (nl) 1997-02-10 1998-08-18 Inst Voor Agrotech Onderzoek Oppervlakte-actieve aminen en glycosiden.
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
EP1860113A1 (en) 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
US7528115B2 (en) * 2006-07-18 2009-05-05 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines
CN101903396A (zh) 2007-11-07 2010-12-01 先灵公司 新的细胞周期关卡调节剂和它们与关卡激酶抑制剂的联合应用
EP2070938A1 (en) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
CA2684017A1 (en) 2009-10-22 2011-04-22 Universite Laval Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US10031142B2 (en) 2010-07-08 2018-07-24 Life Technologies Corporation In situ chemiluminescent substrates and assays
CN102311472B (zh) 2010-07-09 2014-09-03 神隆(昆山)生化科技有限公司 2-氯-9-(2’-脱氧-2’-氟-β-D-***呋喃糖基)-腺嘌呤的制备
EP2705031B1 (en) 2011-05-03 2018-04-11 Life Technologies Corporation Flash and glow 1,2-dioxetanes
US8883800B2 (en) * 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
JP6657182B2 (ja) * 2014-04-25 2020-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
US10068577B2 (en) * 2014-04-25 2018-09-04 Dolby Laboratories Licensing Corporation Audio segmentation based on spatial metadata
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066781A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
EP3322713B1 (en) * 2015-12-03 2021-01-20 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
TWI767937B (zh) 2016-09-09 2022-06-21 美商卡利泰拉生物科技公司 外核苷酸酶抑制劑及其使用方法
BR112019012327A2 (pt) 2016-12-22 2019-11-19 Calithera Biosciences Inc inibidores de ectonucleotidase e métodos de uso dos mesmos
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) * 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN109503587B (zh) * 2017-09-14 2022-01-11 辽宁利锋科技开发有限公司 双杂环三氮唑核苷类似物的抗肿瘤作用与应用
WO2019090111A1 (en) * 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN112423764A (zh) * 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
TW202017569A (zh) * 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
AU2019288495B2 (en) 2018-06-21 2024-02-08 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
CN114008048A (zh) 2019-06-20 2022-02-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法

Also Published As

Publication number Publication date
AU2019288495A1 (en) 2021-01-28
US11078228B2 (en) 2021-08-03
CA3104088A1 (en) 2019-12-26
US20230022922A1 (en) 2023-01-26
BR112020025132B1 (pt) 2023-10-10
CO2021000049A2 (es) 2021-04-19
AU2019288495B2 (en) 2024-02-08
MX2020013320A (es) 2021-02-22
SG11202012001YA (en) 2021-01-28
JP2021529172A (ja) 2021-10-28
CN112888696A (zh) 2021-06-01
IL279475A (en) 2021-01-31
US11858957B2 (en) 2024-01-02
BR112020025132A2 (pt) 2021-03-23
KR20210024561A (ko) 2021-03-05
WO2019246403A1 (en) 2019-12-26
EP3810617A4 (en) 2022-06-29
CN112888696B (zh) 2024-04-16
PH12020552214A1 (en) 2021-08-16
TW202010750A (zh) 2020-03-16
EP3810617A1 (en) 2021-04-28
US20190389899A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP22046699A (es) Inhibidores de kras g12c
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CO2022001453A2 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CO2021010312A2 (es) Inhibidores de la pcsk9 y métodos de uso de los mismos
CL2022003046A1 (es) Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2019008110A2 (es) Activador de nrf2
BR112018072699A2 (pt) determinados inibidores de proteína cinase
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet